|
|
|
|
|
|
|
|
|
27.12.25 - 19:45
|
Senvest Capital Inc. Announces Death of Chief Executive Officer and Chairman of the Board (GlobeNewswire EN)
|
|
|
MONTREAL, Dec. 27, 2025 (GLOBE NEWSWIRE) -- Senvest Capital Inc. (the “Corporation” or “Senvest”) (TSX: SEC) announces with profound sadness the passing of its founder and long-time leader, Victor Mashaal, who served as President, Chief Executive Officer, and Chairman of the Board of Directors. Victor passed away at the age of 87 following a brief illness. He was a deeply respected and admired leader and a mentor to the entire Senvest family. He will be greatly missed....
|
|
|
|
|
07.10.25 - 14:06
|
Jupiter Endovascular Closes Oversubscribed Series B Financing, Surpassing $40 Million Target (Business Wire)
|
|
|
Round Led by Sonder Capital with Participation from Senvest Management, LB Investment, and a New Strategic Corporate InvestorMENLO PARK, Calif.--(BUSINESS WIRE)--#TFX--Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using its proprietary Transforming Fixation (TFX) technology, today announced it has closed an oversubscribed Series B financing that surpassed its $40 million target. The round was led by Sonder Capital, with participation from Senvest Management, LB Investment, and a new strategic corporate investor. The proceeds will be used to complete Jupiter's ongoing SPIRARE II pivotal clinical trial, prepare for commercialization, and develop new clinical applications for its TFX platform technology.
The financing comes between two major milestones: FDA 510(k) clearance last month of the Vertex™ Catheter incorporating TFX, and the upcoming presentation of first-in-human results for the Vertex Pulmonary Embolectomy System with TFX from the SP...
|
|
|
|
|
25.08.25 - 14:33
|
Senvest Capital Inc. Announces Acceptance by TSX of Normal Course Issuer Bid (GlobeNewswire EN)
|
|
|
MONTREAL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Senvest Capital Inc. (the “Corporation”) (TSX: SEC) announced today the acceptance by the Toronto Stock Exchange (the “TSX”) of the Corporation's notice of intention to make a normal course issuer bid (the “NCIB”). Pursuant to the NCIB, the Corporation proposes to purchase, from time to time, if considered advisable, up to an aggregate of 100,000 of its common shares, being approximately 4.12% of its 2,430,024 issued and outstanding common shares as of August 13, 2025, through the facilities of the TSX, other designated exchanges and/or alternative Canadian trading systems or by such other means as may be permitted by the applicable securities regulator. However, due to the historically low volume of trading of its common shares on the TSX, the Corporation advises that actual purchases under the NCIB may in fact be significantly less than 100,000 shares. Purchases may commence on August 27, 2025 and will conclude on the earlier of the date on whi...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
